Generic pharmaceutical company Hikma Pharmaceuticals plc (LSE:HIK) (NASDAQ Dubai:HIK) (OTC:HKMPY) reported on Thursday that its wholly owned US subsidiary Hikma Pharmaceuticals USA Inc has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm.
The drug is indicated to reduce the risk of heart attack, stroke and other types of heart problems.
Icosapent Ethyl Capsules are the generic equivalent to Vascepa, which is a registered trademark of Amarin Pharmaceuticals Ireland Limited.
In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa patents owned by Amarin. The District Court decision is currently being appealed.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling